Latest news with #RECLAIM
Hans India
06-07-2025
- Business
- Hans India
Felicitation ceremony for 7-star and 5-star rated mines to be held on Monday
The Indian Bureau of Mines will host a grand event at the Rajasthan International Centre here on Monday to felicitate the performance of 7 & 5-star rated mines nationwide for the year 2023-24, according to a statement issued by the Ministry of Mines on Sunday. During the event, three 7-star rated mines and 95 5-star rated mines for the year 2023-24 are scheduled to be honoured. The program evaluates mining operations nationwide within the Sustainable Development Framework, which primarily aims to drive inclusive growth while safeguarding the social, economic, and environmental welfare of present and future generations. Union Minister of Coal & Mines G. Kishan Reddy will be the Chief Guest, and Rajasthan Chief Minister Bhajan Lal Sharma and Union Minister of State for Coal & Mines Satish Chandra Dubey will be present as distinguished guests of honour. Sanjay Lohiya, Additional Secretary, Ministry of Mines, will also be present at the occasion. The Star Rating of Mines, conceptualised in 2014-15, has garnered widespread acclaim within the mining community for fostering a positive and competitive environment among mine operators. The recognition bestowed by the Union Minister and the national-level acknowledgement of performance have greatly motivated miners to improve their functioning, bringing tangible benefits to the mining industry as well as the local communities, the statement added. Meanwhile, the Coal Ministry has launched RECLAIM – a community engagement and development framework for mine closures, with the aim of improving both landscapes and local livelihoods. The framework constitutes a key step toward ensuring a just and sustainable transition for communities that have developed alongside mining operations over decades. The framework, referred to as RECLAIM, serves as a structured guide for inclusive community engagement and development throughout the mine closure and post-closure phases. It offers a practical, step-by-step approach to institutionalising community participation in the transition process.
Time of India
02-07-2025
- Business
- Time of India
Coal Ministry to launch RECLAIM framework for inclusive mine closure & community development
Union Minister of Coal and Mines G Kishan Reddy is set to launch RECLAIM – a community engagement and development framework-- on July 4, 2025. This comprehensive framework, developed by the Coal Controller Organisation under the Ministry of Coal in partnership with the Heartfulness Institute, is specifically designed to address the intricate challenges of mine closures and ensure a just transition for affected communities. It will serve as a structured guide for inclusive community engagement and development during both the mine closure and post-closure phases. It provides a practical, step-by-step approach to formalising community participation in this critical transition process. The framework places a strong emphasis on gender inclusivity, ensuring the representation of vulnerable groups, and fostering alignment with Panchayati Raj Institutions. According to the ministry's statement, this integrated approach aims to make the transition process equitable and locally relevant, reflecting the unique needs and perspectives of the communities involved.
Reuters
26-06-2025
- Politics
- Reuters
Europe's top rights court rules against France in racial profiling case
PARIS, June 26 (Reuters) - Europe's top human rights court ruled on Thursday that French police had carried out discriminatory checks on a Frenchman of African descent, the first such verdict in a case of racial profiling brought against France. The French government "failed to provide objective and reasonable justification" for the police carrying out three identity checks on Karim Touil within the space of 10 days in 2011 in the city centre of Besancon, the Strasbourg-based European Court of Human Rights (ECHR) said in its ruling. The court ordered France to pay Touil 3,000 euros ($3,512) for violating articles 14 and 8, on discrimination and the right to a private life, of the European Human Rights Convention. However, for five other applicants in the case, also young men of African descent, the court found there was no discrimination due to lack of evidence, noting that the ID checks had mostly taken place "against a backdrop of tension". While welcoming Touil's successful claim, Lanna Hollo, a rights advocate with French organisation RECLAIM, who has been involved in the case for 13 years, said the court's reasoning risked reinforcing discrimination in certain zones. "It fails to sufficiently protect all people in all parts of the territory - especially those living in France's poorer neighbourhoods with high visible minority populations," she said. In recent years the court has issued rulings against Germany and Switzerland over discriminatory police checks. A study published on Tuesday by France's human rights watchdog found that young Black men or those perceived as Arab or North African were four times more likely to be stopped by police and 12 times more likely to undergo "extensive" checks, involving being body-searched or taken to the police station. ($1 = 0.8542 euros)
Yahoo
19-05-2025
- Health
- Yahoo
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025. RECLAIM is a randomized, placebo-controlled trial being conducted at approximately 15 sites in the United States, with Dr. Henry Kranzler, Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction at the University of Pennsylvania Perelman School of Medicine, serving as the Principal Investigator. The trial is expected to enroll approximately 100 subjects randomized 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks. The primary endpoint of the trial is a change in alcohol consumption, assessed as the change from baseline in the average number of heavy drinking days per week at Week 24, with the key secondary endpoints including the proportion of subjects achieving a 2-level reduction in World Health Organization (WHO) risk drinking level and the absolute change from baseline in average levels of phosphatidylethanol (PEth), a serum biomarker of alcohol intake. An investigational new drug (IND) application for pemvidutide in AUD was filed in December 2024 and was cleared by FDA in January 2025. 'Over 28 million individuals in the U.S. alone have AUD, and the lack of effective treatments has resulted in one of the largest known treatment gaps in this country,' said Dr. Kranzler. 'It has been estimated that less than 10% of patients are currently receiving treatment for AUD and that 2% or less are being treated with any of the 3 medications approved for AUD in the US1. These medications were approved decades ago and have limited beneficial effects and inadequate compliance rates. Thus, there is an urgent need for new therapies for AUD.' 'There are compelling data that GLP-1 agents may reduce the craving for alcohol in addition to reducing food consumption,' said Scott Harris, M.D., Chief Medical Officer of Altimmune. 'In a preclinical hamster model of free-choice alcohol intake, pemvidutide demonstrated a greater than 80% reduction in alcohol preference after the initiation of treatment2. Importantly, AUD is the precursor for alcohol liver disease (ALD), a disease characterized by excess liver fat, liver inflammation and fibrosis with features similar to MASH. In addition, obesity is a major risk factor for MASH, AUD and ALD, and because excess alcohol is a known risk factor for hypertension and dyslipidemia, patients with AUD could benefit further from the metabolic effects of pemvidutide.' About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on X Forward-Looking StatementAny statements made in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, the timing of key milestones for our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and our other filings with the SEC, which are available at Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@ Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@ Media Contact:Jake RobisonInizio Evoke, BiotechPhone: 1 SAMHSA 2023 NSDUH Survey 2 Altimmune R&D Day Presentation, slide #47 This press release was published by a CLEAR® Verified individual.
